| Date Filed | Type | Description |
| 10/10/2023 |
NT 10-Q
| Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB: |
| 08/22/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure... |
| 08/15/2023 |
SC 13D/A
| Cove Street Capital, LLC reports a 5.2% stake in LIFECORE BIOMEDICAL, INC |
| 08/14/2023 |
NT 10-K
| Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405: |
| 07/07/2023 |
SC 13G/A
| BlackRock Inc. reports a 1.8% stake in LIFECORE BIOMEDICAL, INC |
| 06/30/2023 |
SC 13G
| Greenhaven Road Investment Management, L.P. reports a 6.3% stake in LIFECORE BIOMEDICAL, INC. |
| 06/28/2023 |
SC 13D/A
| 22NW Fund, LP reports a 10% stake in Lifecore Biomedical, Inc. |
| 06/12/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 06/09/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 06/06/2023 |
S-1/A
| Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] |
| 06/01/2023 |
4
| Diradoorian Raymond H (Director) has filed a Form 4 on LIFECORE BIOMEDICAL, INC. \DE\|
Txns:
| Exercised 9,474 restricted stock units
@ $0 |
|
| 06/01/2023 |
4
| OBUS NELSON (Director) has filed a Form 4 on LIFECORE BIOMEDICAL, INC. \DE\|
Txns:
| Exercised 9,474 restricted stock units
@ $0 |
|
| 06/01/2023 |
4
| EDWARDS JEFFREY L (Director) has filed a Form 4 on LIFECORE BIOMEDICAL, INC. \DE\|
Txns:
| Exercised 9,474 restricted stock units
@ $0 |
|
| 06/01/2023 |
4
| HOUDE LOVAS KATRINA (Director) has filed a Form 4 on LIFECORE BIOMEDICAL, INC. \DE\|
Txns:
| Exercised 9,474 restricted stock units
@ $0 |
|
| 06/01/2023 |
4
| Barbarosh Craig A. (Director) has filed a Form 4 on LIFECORE BIOMEDICAL, INC. \DE\|
Txns:
| Exercised 9,474 restricted stock units
@ $0 |
|
| 06/01/2023 |
4
| Schechter Joshua (Director) has filed a Form 4 on LIFECORE BIOMEDICAL, INC. \DE\|
Txns:
| Exercised 9,474 restricted stock units
@ $0 |
|
| 06/01/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 05/22/2023 |
8-K
| Credit agreement amendment |
| 04/14/2023 |
8-K
| Quarterly results |
| 04/06/2023 |
8-K
| Asset disposition |
| 03/27/2023 |
8-K/A
| Financial Statements and Exhibits Interactive Data |
| 03/16/2023 |
8-K
| Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits I... |
| 03/16/2023 |
SC 13D/A
| WYNNEFIELD PARTNERS SMALL CAP VALUE LP I reports a 16.6% stake in LIFECORE BIOMEDICAL, INC. |
| 03/16/2023 |
10-Q
| Quarterly Report for the period ended November 27, 2022 |
| 03/16/2023 |
10-Q/A
| Quarterly Report for the period ended August 28, 2022 [amend] |
| 03/16/2023 |
10-K/A
| Annual Report for the period ended May 29, 2022 [amend] |
| 03/07/2023 |
SC 13D/A
| WYNNEFIELD PARTNERS SMALL CAP VALUE LP reports a 17.9% stake in LIFECORE BIOMEDICAL, INC. |
| 02/10/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/07/2023 |
8-K
| Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets Interactive Data |
| 02/02/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/02/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/02/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/02/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/02/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
|